Activase (alteplase) News

«1 2...17 18 19 20 212223 24 25 26 27...53 54 »

|||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Risk of Distal Embolization in Large Vessel Occlusion Strokes Treated with Tenecteplase (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2657;
The exclusion of tandem and/or ICA occlusions due to small sample size was a significant limitation of the study that affects generalizability to the strokes secondary to LVO. The trend towards statistical significance in higher distal embolization rates in subjects receiving TNK warrants larger, prospective studies to validate results.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Association Of Hemoglobin Over The First Week With Clinical Outcomes And Neuroimaging Characteristics In Patients With Spontaneous Intracerebral Hemorrhage () - Mar 6, 2022 - Abstract #AAN2022AAN_2163;
In patients with ICH, higher nadir HB in the first week was associated with better long-term FO and smaller ICH volumes. Early HB changes may serve as a prognostic biomarker and a potentially modifiable factor to improve FO.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Thrombolysis for Acute Ischemic Stroke in Patients with versus without Pre-morbid Disability: A Meta-analysis ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_2091;
However, discussions regarding thrombolysis in this group should acknowledge their much higher mortality and potentially higher sICH risk, although it is unknown if this can be attributed to treatment. High-quality data comparing treated versus untreated patients with pre-morbid disability are needed to clarify this issue.

|||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Tenecteplase is Safe and Efficacious in Telestroke Patients with Confirmed Large Vessel Occlusions () - Mar 6, 2022 - Abstract #AAN2022AAN_1625;
High-quality data comparing treated versus untreated patients with pre-morbid disability are needed to clarify this issue. Telestroke patients with confirmed LVO and treated with tenecteplase were found to have better 90 day outcomes compared to patients treated with alteplase, without increased complication rates.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Functional Status at 30 and 90 Days After Mild Ischemic Stroke () - Mar 6, 2022 - Abstract #AAN2022AAN_1555;
Telestroke patients with confirmed LVO and treated with tenecteplase were found to have better 90 day outcomes compared to patients treated with alteplase, without increased complication rates. A quarter of mild ischemic stroke participants exhibited functional changes between 30-90 days, suggesting that the 30-day outcome may insufficiently represent long-term recovery in mild stroke and longer follow-up may be clinically necessary.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Effectiveness of Standard-Dose vs. Low-Dose Alteplase for Acute Ischemic Stroke Within 3-4.5 h. (Pubmed Central) - Mar 4, 2022
In the 3-4.5 h time window, the effectiveness and safety of standard-dose and low-dose alteplase may be comparable. A standard dose may be selected for patients with cardioembolism, atrial fibrillation, or hypercholesterolemia.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. (Pubmed Central) - Mar 3, 2022
Of the secondary functional outcomes, 4 of 7 showed significant differences in favor of the NOAC group after adjustment, including the proportion of patients discharged home (45.9% vs 53.6% for patients not taking anticoagulants; adjusted OR, 1.17 [95% CI, 1.06 to 1.29]; adjusted RD, 3.84% [95% CI, 1.46% to 6.22%]). Among patients with acute ischemic stroke treated with intravenous alteplase, use of NOACs within the preceding 7 days, compared with no use of anticoagulants, was not associated with a significantly increased risk of intracranial hemorrhage.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Perceived acceptable uncertainty regarding comparability of endovascular treatment alone versus intravenous thrombolysis plus endovascular treatment. (Pubmed Central) - Mar 3, 2022
Physicians would generally feel comfortable skipping IVT before EVT at different certainty thresholds. Most physicians would treat with EVT alone if randomized trial data suggested that the number of patients achieving functional independence at 90 days was similar between the two groups, and one could be sufficiently sure that no more than 3 out of 100 patients would not achieve functional independence at 90 days due to skipping IVT.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Intra-arterial Alteplase After Successful Thrombectomy and Functional Outcomes in Large Vessel Occlusion... https://t.co/ZJivQqrgFQ vía @JAMA_current part of @JAMANetwork (Twitter) - Mar 1, 2022

|||||||||| spironolactone / Generic mfg.
Journal: Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis. (Pubmed Central) - Mar 1, 2022
Moreover, some repurposed medications have already shown beneficial effects on infertility treatment. These previous experimental reports confirm our suggestion for investigating our other repurposed drugs (in vitro and in vivo).

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Retrospective data, Journal: Patient-Reported Anxiety/Depression After Endovascular Thrombectomy: A post-hoc Analysis of Direct-MT Trial. (Pubmed Central) - Mar 1, 2022
P=N/A
It may also indicate that it is better to provide IV alteplase before EVT, rather than EVT alone according to patient-reported anxiety/depression. Future research should consider not only the motor function impairments but also the patient-reported mental problems as measures of treatment efficacy in patients with stroke (DIRECT-MT ClinicalTrials.gov number, NCT03469206).

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Correction to: Effect of Occlusion Site on the Safety and Efficacy of Intravenous Alteplase Before Endovascular Thrombectomy: A Prespecified Subgroup Analysis of DIRECT-MT. (Pubmed Central) - Mar 1, 2022
Future research should consider not only the motor function impairments but also the patient-reported mental problems as measures of treatment efficacy in patients with stroke (DIRECT-MT ClinicalTrials.gov number, NCT03469206). No abstract available

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Effectiveness and Predictors of Poor Prognosis Following Intravenous Thrombolysis in Patients with Wake-Up Ischemic Stroke Guided by Rapid MRI. (Pubmed Central) - Feb 26, 2022
Our aim was to investigate the effectiveness and predictors of poor prognosis in WUIS patients who received alteplase thrombolysis under the guidance of diffusion-weighted imaging (DWI)-T2-weighted imaging (T2WI) mismatch...The DWI-T2WI sequence is an effective method to guide intravenous thrombolytic therapy for WUIS. Baseline NIHSS score and atrial fibrillation were identified as independent predictors of poor prognosis following thrombolysis in WUIS patients.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Intravenous Alteplase at 0.6 mg/kg for Unknown Onset Stroke with Prior Antithrombotic Medication: THAWS Randomized Clinical Trial. (Pubmed Central) - Feb 25, 2022
Baseline NIHSS score and atrial fibrillation were identified as independent predictors of poor prognosis following thrombolysis in WUIS patients. Alteplase appears more beneficial in patients with prior antithrombotic medication.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Biomarker, Journal: Early neutrophil-to-lymphocyte ratio is a prognostic marker in acute minor stroke or transient ischemic attack. (Pubmed Central) - Feb 23, 2022
Intravenous injection of alteplase is recommended for patients with minor disabling and not non-disabling ischemic stroke symptoms within 4.5 h of ischemic stroke symptom onset...Early neutrophil-to-lymphocyte ratio is associated with short-term unfavorable functional outcome in patients with acute minor stroke or transient ischemic attack. Early neutrophil-to-lymphocyte ratio is beneficial for clinicians to distinguish minor disabling ischemic stroke at an early stage.

|||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Tenecteplase Versus Alteplase For Large Vessel Occlusion Recanalization: T-FLAVOR Trial (Hall B2, Poster Hall; Board No. CTP3) - Feb 22, 2022 - Abstract #ISC2022ISC_1748;
Trial status: Study start date is 1st Oct. 2021 and now recruiting.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Prof. Dr. DWJ Dippel (Hall B2, Poster Hall; Board No. CTP20) - Feb 22, 2022 - Abstract #ISC2022ISC_1741;
P2
Secondary outcomes include symptomatic ICH, NIHSS scores at 24 hours and 5-7 days, and mRS score at 30 days.ResultsFirst patient was included August 10th, 2019. Currently, 134 patients are included.ConclusionsWe hypothesize that dual thrombolytic therapy with a bolus alteplase and m-pro-urokinase will reduce the occurrence of ICH in patients with ischemic stroke comparedwith patients treated with alteplase alone.

|||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Randomization To Endovascular Treatment Alone Or Preceded By Systemic Thrombolysis With Tenecteplase In Acute Ischemic Stroke Due To Large Intracranial Vessel Occlusion Trial -direct Thrombectomy Vs. Intravenous Tnk Plus Thrombectomy - RESILIENT DIRECT TNK (Hall B2, Poster Hall; Board No. CTP11) - Feb 22, 2022 - Abstract #ISC2022ISC_1731;
Outcome: The primary outcome will be the ordinal distribution from the modified Rankin scale score (mRS) at 90 days.Trial Status: Enrolling starting in November, 2021. Fourteen sites already IRB approved and ready for enrollment.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Impact Of Regionalization Of Stroke Systems Of Care In The Stroke Belt States Of North And South Caroline; The Improve Stroke Care Program. (Riverside Room R02-R05) - Feb 22, 2022 - Abstract #ISC2022ISC_1477;
Prehospital notification by EMS increased from 42% to 79% (p<0.0001) and stroke severity scoring went up from 25% to 55% (p<0.0001). Median DTN times among EMS transported patients decreased from 41 min.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Outcomes In Patients Who Receive Endovascular Thrombectomy With Or Without Alteplase: Findings From Get With The Guidelines-Stroke (Riverside Room R02-R05) - Feb 22, 2022 - Abstract #ISC2022ISC_1476;
Median DTN times among EMS transported patients decreased from 41 min. In this observational study of patients treated with EVT, intravenous alteplase treatment was associated with better in-hospital survival and functional outcomes, but higher sICH risk after adjusting for other covariates.

|||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Tenecteplase Thrombolysis For Stroke Up To 24 Hours After Onset With Perfusion Imaging Selection (Hall D) - Feb 22, 2022 - Abstract #ISC2022ISC_1337;
P2
Trial Registration Number: NCT04086147 Background and Aims: Growing evidence supports Tenecteplase (TNK) is noninferior to alteplase in acute ischemic stroke, and even superior to alteplase in patients with large vessel occlusions within 4.5 hours of onset. To be determined.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
A Randomized Trial Of Intraarterial Alteplase After Successful Thrombectomy In Acute Ischemic Stroke (Hall D) - Feb 22, 2022 - Abstract #ISC2022ISC_1336;
P2
The median (IQR) time from symptom onset to randomization was 318 (229-641) minutes, and from symptom onset to start the study medication was 328 (240-676) minutes, without significant differences between the groups. The primary outcome effect, the secondary efficacy outcomes, the safety outcomes and the predefined subgroup analysis will presented at the conference (Funded by the Marató of TV3; CHOICE ClinicalTrials.gov number, NCT03876119).

|||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Pick Your Poison: Tenecteplase Versus Alteplase in the 4.5 Hr Window (Riverside Room R02-R05) - Feb 22, 2022 - Abstract #ISC2022ISC_1208;

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Pro: Late Window Thrombolysis is Indicated with Alteplase or TNK for All Patients Who Meet Eligibility Either by DWI-FLAIR Mismatch or Perfusion Mismatch (Riverside Room R02-R05) - Feb 22, 2022 - Abstract #ISC2022ISC_1206;

|||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Review, Journal: Diagnosis and Treatment of Acute Coronary Syndromes: A Review. (Pubmed Central) - Feb 22, 2022
For patients with STEMI, coronary catheterization and PCI within 2 hours of presentation reduces mortality, with fibrinolytic therapy reserved for patients without access to immediate PCI. For high-risk patients with NSTE-ACS without contraindications, prompt invasive coronary angiography followed by percutaneous or surgical revascularization is associated with lower rates of death.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Frequency and Prognostic Significance of Clinical Fluctuations Before Hospital Arrival in Stroke. (Pubmed Central) - Feb 19, 2022
P=N/A
Fluctuations in neurological symptoms and signs are common in the prehospital setting. Prehospital improvement was associated with better 90-day outcomes, controlling for admission NIHSS and alteplase treatment.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical: Intravenous Alteplase Treatment of Acute Ischemic Stroke Patients Exhibiting Mild Neurological Deficits. (Pubmed Central) - Feb 19, 2022
Intravenous rt-PA administration is associated with improved functional outcomes at three months after the stroke in mild ischemic stroke patients. Key Words: Acute ischemic stroke, Mild, Alteplase, Meta-analysis.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
A Case of Tuberculous Pleural Effusion (Area K, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1524;
It also reinforces the use of pleural biopsy in diagnosis of this effusion. Early diagnosis and therapeutic drainage, along with tuberculosis treatment can prevent the patient from having more severe residual pleural thickening with long-term effects.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Use of Fibrinolytics for Infectious Pleural Effusions - Alteplase Vs Alteplase and Dornase, a Real-World Experience in a Major Tertiary Referral Center (Area K, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1493;
The use of combination lytic therapy with alteplase and dornase for infectious pleural effusions resulted in decreased surgical intervention (14.9%) compared to alteplase only (22.7%). There were no differences in the hospital LOS and duration of chest tube drainage.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Wrong Bug in Wrong Space - A Case of Spontaneous Bacterial Empyema (Area K, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1468;
SBEM is a rare complication of hepatic hydrothorax whose exact mechanism is yet to be investigated as lung parenchyma is not involved in the infective process. Given the rarity of incidence, SBEM should also be considered in patients with hepatic hydrothorax to avoid delay in diagnosis and further management.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Not Every Filling Defect Is a Thrombus (Area B, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1451;
Echocardiography with dilatation of the right cavities with contractile dysfunction of the RV wall and positive McConell's sign with PSAP of 70 mmHg, for which it was indicated pharmacological thrombolysis (alteplase) and therapeutic anticoagulation...A week later, an echo and control CT angiography were performed, without significant changes, for it was decided to start empirical chemotherapy based on Etoposide and Cisplatin...This metastatic gestational trophoblastic tumor was classified as high risk due to elevated hCG levels and hemodynamic and respiratory compromise. Therefore, he received combination chemotherapy, with rapid clinical and biochemical improvement.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Half Dose and Rescue Thrombolysis in Acute Pulmonary Embolism from Covid-19 (Area B, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1440;
There were no major bleeding events after thethrombolysis.ConclusionOur findings suggest that for patients with intermediate-low risk but with signs of clinicaldeterioration, giving rescue doses of alteplase may address the PE and significantly improvethe patient’s clinical status. Administration of half dose thrombolysis may be beneficial forpatients with intermediate-high risk PE but with high-risk features such as massivepulmonary embolism.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
A Thrombus in Transit: The Power of Point of Care Ultrasonography in Critically Ill Patients (Area B, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1435;
She underwent thrombectomy without alteplase and demonstrated improvement of her left sided weakness...In our patient, bedside POCUS revealed a thrombus in transit in the RV before her acute decompensation, allowing us to consider early interventions. Repeat bedside POCUS following the acute decompensation showed that the thrombus was no longer present

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Papillary Muscle... in Transit? (Area B, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1434;
Alteplase was considered but deferred pending CTS evaluation...The patient was started on IV Epoprostenol and oral Sildenafil...This case also demonstrates the effects of anchoring bias. The cardiology fellow evaluating the bedside echocardiography images was looking for signs of a pulmonary embolism, and the attending cardiology physician that subsequently reviewed the images was notified of a possible clot in transit.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Experience of Reduced Dose Alteplase in Patients with Pulmonary Embolism Intermediate-High-Risk: A Single Centre Study (Area B, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1419;
Pulmonary embolisim response team help to treatment decision handling challenges. According to preliminary results of our study, reduced-dose alteplase can be applied in selected patients with intermediate-high risk.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Major Airway Obstruction by Carbonaceous Fibrin Casts in a Child Due to Smoke Inhalation Injury (Area E, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1317;
Treatment was initiated with nebulized alteplase and heparin...This case also demonstrates the limitations of ETT-nebulized delivery as large carbonaceous casts remained in the upper airway despite therapy. This confirms the importance of evaluation and treatment of the entire respiratory tract for possible involvement, including regions below and proximal to the ETT.

|||||||||| Orencia (abatacept) / BMS, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Rheumatoid Lung Treated with Lytic Therapy (Area F, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_949;
At present, the best studied indication for intrapleural tPA/DNase is in patients with an infected pleural space. Our case demonstrates the broader role that intrapleural tPA/DNase may have in complex exudative effusions, especially of inflammatory/autoimmune etiology, and the need for future studies to more definitely explore this utility.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Effect of Occlusion Site on the Safety and Efficacy of Intravenous Alteplase Before Endovascular Thrombectomy: A Prespecified Subgroup Analysis of DIRECT-MT. (Pubmed Central) - Feb 17, 2022
P=N/A
In this prespecified subgroup of a randomized trial, we found no evidence that occlusion location can inform intravenous alteplase decisions in endovascular treatment eligible patients directly presenting at endovascular treatment capable centers. Future studies are needed to confirm our findings.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
No sir, I argue it is Alteplase😃. (Twitter) - Feb 16, 2022

|||||||||| enoxaparin sodium / Generic mfg.
First Clinical Manifestation of a KILT syndrome in a 12-year-old boy. (hall 1; hall 2; hall 3; hall 4; hall 5) - Feb 16, 2022 - Abstract #GTH2022GTH_269;
Anomaly of the IVC is a rare example of a prevalent congenital condition that predisposes to DVT and even to prenatal/neonatal renal thrombosis with consecutive kidney atrophy. We suggest that children with an unprovoked lower extremity DVT undergo further imaging to evaluate for coexisting IVC and renal abnormalities.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
This is an important paper. What leads to a TICI 2 result after thrombectomy is often incomplete microvascular reperfusion (IMR) — aka no reflow phenomenon Intra-arterial Alteplase After Successful Thrombectomy https://t.co/B40TPNfPi3 (Twitter) - Feb 15, 2022

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical: Recent Use of NOACs not Associated w/ Increased Intracranial Hemorrhage Risk in Patients w/ #Stroke Treated With Alteplase https://t.co/zYjtq78ItT via @JAMA_current part of @JAMANetwork @Braindoc_MGH @Braindoc_MGH @AHAScience @StrokeAHA_ASA @texhern @ericpetersonMD @YingXian21 (Twitter) - Feb 10, 2022

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical: Recent Use of NOACs and Intracranial Hemorrhage in Patients With Stroke Treated With Alteplase https://t.co/jHfK9GKFMY via @JAMA_current part of @JAMANetwork @Braindoc_MGH @ericpetersonMD @YingXian21 @DCRINews @AHA_Research @AHAScience #GWTG (Twitter) - Feb 10, 2022

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: INTRAVENOUS THROMBOLYTIC THERAPY FOR ACUTE NONARTERITIC CENTRAL RETINAL ARTERY OCCLUSION. A REVIEW. (Pubmed Central) - Feb 9, 2022
Summary statistics of patient data from relevant studies indicate that a significant visual acuity improvement was achieved by a total of 45 % of patients receiving alteplase within 4.5 hours of symptoms onset...The intravenous thrombolysis administration, patient monitoring, etiologic workup, and setting of effective secondary prevention should be ensured at the centre of highly specialized cerebrovascular care. Urgent transport of the CRAO patient to the nearest centre is essential.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. (Pubmed Central) - Feb 9, 2022
Urgent transport of the CRAO patient to the nearest centre is essential. No abstract available

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. Reply. (Pubmed Central) - Feb 9, 2022
No abstract available No abstract available

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Prolonged Intra-Sinus Alteplase Infusion in Severe Case of CVST. (Pubmed Central) - Feb 8, 2022
Unfortunately, she continued to deteriorate despite maximal medical therapy. She was made comfort care and expired.

|||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Clinical protocol, P3 data, Journal, Head-to-Head: Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial. (Pubmed Central) - Feb 8, 2022
P3
The best management of SMH is unknown. TIGER aims to establish if the benefits of SMH surgery outweigh the risks, relative to aflibercept monotherapy.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Feasibility and safety of catheter-directed thrombolysis via superficial cubital vein for the treatment of acute massive and submassive pulmonary embolism. (Pubmed Central) - Feb 8, 2022
CDT included mechanical thrombus fragmentation and the local application of adjuvant thrombolytic therapy through the pigtail catheter - alteplase administered as 2.5 mg bolus in each main branch of the pulmonary artery plus adjuvant 25 mg for 12 h in the more severely affected branch of the pulmonary artery...CDT by using the cubital approach is a simple, safe, and feasible treatment option for PE. This approach was associated with significant improvement in hemodynamic parameters without fatal outcomes or major periprocedural complications.

|||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Stroke due to Percheron Artery Occlusion: Description of a Consecutive Case Series from Southern Portugal. (Pubmed Central) - Feb 4, 2022
Stroke from AOP presents with variable clinical and radiological presentations and patients do not receive alteplase. The short-term survivor and the long-term functional independency can be compromised after AOS infarct.



	Diseases Companies Products Productz Mechanisms of Action Sites